2012 9M: Results note

New quarter of operational recovery in Forté Pharma

  • After a decline in turnover of 19.5% in the first quarter, the positive development of sales in the following quarters (+3.4% in 2Q and +8.8% in 3Q stand) placed Natraceutical’s turnover at 23.59 M€ (-6.4% compared to September 2011).
  • Operational optimization policies implemented throughout the year enabled the company to bring its EBITDA to 1.78 M€ in September 2012, compared to -0.64 M€ in the third quarter of 2011.
  • Despite Forté Pharma’s operational improvement, Natraceutical closed the third quarter with a net loss of 0.28 M€ compared to net income of 1.48 M€ in September 2011. The difference was mainly due to the variation in the contribution of Naturex to Natraceutical’s accounts in these two years (6.52 M€ up to September 2011 compared to 1.40 M€ to September 2012).
  • At the end of the third quarter, the value of the financial investment in Naturex rose 72.52 M€, while net financial debt stood at 50.23 M€, compared to 75.40 M€ at 30 September 2011.

Download original text (PDF)